Tenofovir's price has been greatly reduced. Is it far for the latest hepatitis C drugs to be introduced into China?

Source: after the price negotiation of nai500 2016-08-02, the price of tenofovir, a hepatitis B drug, has been greatly reduced in China, which may pave the way for cutting-edge hepatitis C drugs to enter China in the same way Earlier this year, tenofovir, a hepatitis B drug developed by Gilead Science in the United States and sold in China by GlaxoSmithKline in the United Kingdom, announced a sharp price cut in China and included in the coverage of medical insurance reimbursement The move is expected to significantly increase sales of the drug in China Cai Haodong, a professor of infectious diseases at Ditan hospital in Beijing, said the price of tenofovir is less than 500 yuan, which is significantly lower than 1500 yuan before the price negotiation Bernhard schwart ­ L ä nder, who representative in China, said prices were also a key factor for hepatitis C drugs "Only when patients have access to these drugs at affordable prices can their lives be saved," he said He pointed out that unless the Chinese government takes action, about 10 million chronic hepatitis patients in China will face "mostly avoidable deaths" by 2030 Patients are also calling on the state to approve hepatitis C drugs as soon as possible Up to now, the Sino US joint venture World Pharmaceutical (Hangzhou) Co., Ltd is vigorously promoting the listing of the first modern therapy in China, and the approval of the listing of hepatitis C drugs by Bristol Myers Squibb and Gilead Science Co., Ltd is nearing the end China is in discussions with Gilead science about the pricing of hepatitis C drugs, and it is unclear whether it includes epclusa At present, the drug has entered 100 developing countries in the world through the production and licensing agreements between Gilead science and several enterprises in India China is not within the scope of the license agreement According to media reports, China hopes to guide prices no higher than six neighboring markets, including India.